Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Shares Bought by Pallas Capital Advisors LLC

Pallas Capital Advisors LLC lifted its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 61.8% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 3,321 shares of the biopharmaceutical company’s stock after acquiring an additional 1,269 shares during the period. Pallas Capital Advisors LLC’s holdings in Alnylam Pharmaceuticals were worth $975,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in ALNY. Ashton Thomas Private Wealth LLC acquired a new position in Alnylam Pharmaceuticals in the second quarter valued at $26,000. Allspring Global Investments Holdings LLC grew its holdings in Alnylam Pharmaceuticals by 572.0% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 168 shares of the biopharmaceutical company’s stock valued at $25,000 after buying an additional 143 shares during the period. Friedenthal Financial acquired a new position in shares of Alnylam Pharmaceuticals during the 3rd quarter valued at about $51,000. Altitude Crest Partners Inc. purchased a new position in shares of Alnylam Pharmaceuticals during the 1st quarter worth about $30,000. Finally, Meeder Asset Management Inc. boosted its position in shares of Alnylam Pharmaceuticals by 1,237.5% in the second quarter. Meeder Asset Management Inc. now owns 321 shares of the biopharmaceutical company’s stock worth $78,000 after acquiring an additional 297 shares during the last quarter. Hedge funds and other institutional investors own 92.97% of the company’s stock.

Alnylam Pharmaceuticals Stock Performance

Shares of ALNY opened at $284.69 on Wednesday. Alnylam Pharmaceuticals, Inc. has a one year low of $141.98 and a one year high of $304.39. The stock has a 50-day moving average price of $274.75 and a 200 day moving average price of $224.30. The company has a market capitalization of $36.01 billion, a P/E ratio of -106.23 and a beta of 0.39.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its earnings results on Thursday, August 1st. The biopharmaceutical company reported ($0.13) EPS for the quarter, beating the consensus estimate of ($0.74) by $0.61. The business had revenue of $659.83 million for the quarter, compared to analysts’ expectations of $447.22 million. The business’s quarterly revenue was up 107.0% compared to the same quarter last year. During the same quarter last year, the company posted ($2.21) earnings per share. As a group, equities research analysts forecast that Alnylam Pharmaceuticals, Inc. will post -2.73 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, CEO Yvonne Greenstreet sold 15,148 shares of the company’s stock in a transaction dated Thursday, August 1st. The shares were sold at an average price of $270.00, for a total value of $4,089,960.00. Following the sale, the chief executive officer now owns 73,441 shares in the company, valued at approximately $19,829,070. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In other news, CEO Yvonne Greenstreet sold 15,148 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Thursday, August 1st. The stock was sold at an average price of $270.00, for a total value of $4,089,960.00. Following the completion of the transaction, the chief executive officer now owns 73,441 shares in the company, valued at approximately $19,829,070. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Dennis A. Ausiello sold 20,250 shares of the business’s stock in a transaction that occurred on Tuesday, August 6th. The shares were sold at an average price of $262.00, for a total value of $5,305,500.00. Following the completion of the sale, the director now owns 136 shares of the company’s stock, valued at $35,632. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 50,398 shares of company stock valued at $13,595,460 in the last ninety days. Corporate insiders own 1.50% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on the stock. Barclays increased their price target on shares of Alnylam Pharmaceuticals from $291.00 to $295.00 and gave the stock an “overweight” rating in a research note on Friday, August 2nd. JPMorgan Chase & Co. increased their target price on Alnylam Pharmaceuticals from $248.00 to $280.00 and gave the stock a “neutral” rating in a research report on Monday, August 26th. Morgan Stanley boosted their price target on Alnylam Pharmaceuticals from $250.00 to $255.00 and gave the company an “equal weight” rating in a research report on Friday, July 12th. Needham & Company LLC restated a “buy” rating and issued a $320.00 price objective on shares of Alnylam Pharmaceuticals in a report on Thursday, October 10th. Finally, Bank of America boosted their target price on Alnylam Pharmaceuticals from $307.00 to $314.00 and gave the stock a “buy” rating in a report on Monday, October 14th. Six research analysts have rated the stock with a hold rating and nineteen have given a buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $290.86.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.